"Ligand-binding, Flow Cytometry, PCR and ELISpot Assays"
Part 1: Immunogenicity Assays
-
Topic 1:
How to think about Immunogenicity & Bioanalysis for Drugs that have a Prolongation Effect in vivo
-
Topic 2:
T-cell Engager (BiTE) Immunogenicity & Associated Cytokine Release: Pasotuximab Lesson Learned and Cytokine Measurement Strategy
-
Topic 3:
Target Interference on Screening Assays Cut Point & Importance of Risk Assessment for pH Sensitive Multi-domain Biotherapeutic (MDB): Lessons learned from Immunogenicity Assays for MDB
-
Topic 4:
Characterization of “high” Incidence Clinical ADA beyond ADA and NAb Assay Testing: What would drive additional characterization and its timing?
-
Topic 5:
Understanding the Affinity of ADA in Clinical Samples in Connection with LBA: What expected & What unexpected
Part 2: Biomarker Assays & PK Assays
-
Topic 6:
The Evolving in the Field of Extracellular Vesicles Bioanalysis: Latest Developments and Next Steps
-
Topic 7:
Challenges in Biomarker Assay Validation (BAV) for Primary/Secondary End Points in Clinical Studies: CAP/CLIA beyond BMV Guidance & Using newly developed non-IVD vs. FDA approved IVD
-
Topic 8:
A decade of Free/Total Assays Discussions for Biomarker Assays & PK Assays: Where do we stand and what could be the next step in developing the “ultimate” strategy?
- Importance of Clearly Defined Free/Total Bioanalytical Data to Evaluate the Pharmacokinetic Behavior of Therapeutic Proteins and to Enable PK/PD assessment - Topic 8a
- Target Assay Strategy: Why do we Measure Target and How do we use the Data? - Topic 8b
- Free/Complex/Total Target Engagement (TE) Measurements: Is there a real need to develop multiple assays with overlapping purposes? - Topic 8c
Part 3: Gene Therapy, Cell Therapy and Vaccine Assays
-
Topic 9:
Challenges with the use of Cell-based Assays as Vaccine Clinical Studies Endpoints: Why not move to Plate-based assays?
-
Topic 10:
Implementation of a Bridging LBA to assess ADA response to CAR-T therapy and correlation with Cell-Based/Flow Cytometry data
-
Topic 11:
Lesson Learned on Gene Therapy Immunogenicity Strategy: Pre-existing Immunity, Utility of NAb assays, Cellular Immunity, ELISpot result… What data/assays are really needed?
-
Topic 12:
Lesson Learned on CAR-T Bioanalytical Strategy: Cellular Immunity/CTL Response, Utility of NAb assays, ELISpot Inconsistent result, qPCR/ddPCR/NGS for Gene Expression Analysis...What data/assays are really needed?
Part 4: White Paper in Bioanalysis
-
2022 White Paper on Ligand-binding, Flow Cytometry, PCR and ELISpot Assays:
Consensus & Conclusions on Ligand-binding, Flow Cytometry, PCR and ELISpot Assays for 2022 White Paper
